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interpreted as an expensive learning 
experience, and future trials should be 
aimed at speciﬁc age ranges. The gaunt-
let has now been thrown down for other 
outcomes studies in nephrology, and 
in particular those relevant to mineral 
and bone disorders in patients with 
chronic kidney disease. This includes 
studies on vitamin D metabolites. For 
example, is there any real benefit to 
analogs of 1α,25-dihydroxyvitamin D 
over 1α,25(OH)-vitamin D itself or 
the prodrug 1α(OH)-vitamin D? This 
has never been studied and is an open 
question, and we can only hope that the 
challenges are taken up.
In summary, DCOR was an ambitious 
and well performed study. It really was 
essentially a negative study, as younger 
patients showed a tendency to beneﬁt 
from calcium-based P binders and, in 
older patients, if there was really a beneﬁt 
to sevelamer, it was not shown to be due 
to any change in cardiovascular mortal-
ity. So intuitively it may sound correct to 
give a non-calcium-based P binder, but 
we await DCOR II for a more deﬁnitive 
study to know whether our intuition is 
based on science or skilled marketing.
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Exosomes in urine: Who would have 
thought…?
MA Knepper1 and T Pisitkun1
Normal urine contains thousands of proteins, largely due to the presence 
of  ‘exosomes,’ tiny vesicles secreted into the urine by renal epithelial 
cells. These exosomes, demonstrated by Keller and colleagues to be also 
retrievable from amniotic fluid, offer great promise for future disease 
biomarker discovery studies.
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Who would have thought…? Who would 
have thought that urine could be so complex? 
For hundreds of years, physicians have ana-
lyzed urine in a variety of ways to discover 
what is wrong with their patients.1 Most 
frequently, we divide samples into two 
components (sediments and supernatant) 
and look with interest at the sediments for 
the telltale crystal, cast, or cell that will give 
us a clue to what is happening upstream in 
the kidney. The supernatant, or a sample 
of whole urine, meanwhile is examined 
chemically for a few properties that can 
provide added clues — albumin? glucose? 
hemoglobin? — and skilled physicians 
succeed with these simple measures, even 
today, for the beneﬁt of their patients. We 
have grown comfortable with the idea that 
urine is a very simple ﬂuid.
But new developments have painted a 
diﬀerent picture of normal urine, a picture 
of complexity, and the ﬁndings presented 
by Keller and colleagues2 (this issue) have 
added additional important details.2 The 
ﬁrst signs of complexity were early reports 
from proteomics studies using sensitive 
mass spectrometers that normal urine 
contains hundreds of proteins (albeit at low 
concentrations), including integral mem-
brane proteins.3,4 Another sign was the 
discovery that urine contains solid-phase 
elements that remain in the supernatant at 
standard centrifugation speeds for most 
laboratory centrifuges, but which can be 
pelleted at much higher centrifugation 
speeds, that is, via ultracentrifugation. 
A major component of these high-speed 
sediments turned out to be ‘exosomes,’ 
tiny (40–80 nm) membranous structures 
secreted by epithelial cells5 (Figure 1a). 
These urinary exosomes were demon-
strated to contain abundant aquaporin-2, 
providing an explanation for the earlier 
unexplained ﬁnding that the water chan-
nel aquaporin-2, an integral membrane 
protein, was plentiful in urine.6 It turns 
out that many of the myriad of proteins 
detected in urine by mass spectrometry 
in those early proteomics studies are there 
because of the presence of exosomes in 
normal urine.
Exosomes are membrane-bound vesi-
cles that originate as the internal vesicles 
of multivesicular bodies (MVBs; Figure 
1b) in various cell types and are released to 
the extracellular environment by fusion of 
the outer membrane of the MVBs with the 
plasma membrane. Exosomes were previ-
ously known to be produced by many cell 
types, including B lymphocytes and eryth-
rocytes, from which they are delivered 
into the blood. The ﬁnding of exosomes in 
the urine (Figure 1a) opened up new pos-
sibilities for the diagnosis of kidney dis-
eases. Pisitkun et al.5 carried out tandem 
mass spectrometric proﬁling of proteins 
present in urinary exosomes from normal 
human subjects and found 295 distinct 
proteins, at least 22 of which had already 
been implicated in various kidney and sys-
temic abnormalities. Subsequent studies 
using more sensitive mass spectrometric 
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methods have identiﬁed even more pro-
teins (our unpublished data). The pro-
teome of urinary exosomes includes 
proteins that are characteristic of every 
renal tubule epithelial cell type, as well as 
podocytes and transitional epithelia from 
the urinary collecting system. Not only do 
the exosomes contain membrane proteins, 
but their lumina contain cytosolic proteins 
trapped during the formation of MVBs. 
These ﬁndings open the door for the use of 
urinary exosomes in biomarker discovery 
experiments, aimed at revealing markers 
that could be used for low-cost screen-
ing for early detection of renal disease, for 
subclassiﬁcation of renal diseases, and for 
therapeutic monitoring. With this objective 
in mind, we and others have been develop-
ing a technical infrastructure for eﬃcient 
urinary exosome isolation, storage, and 
analysis.7 Two web sites provide technical 
protocols (http://intramural.niddk.nih.
gov/research/uroprot/) and a urinary exo-
some proteomics database (http://dir.nhlbi.
nih.gov/papers/lkem/exosome/index.htm) 
for use by the general public.
The report by Keller and colleagues2 (this 
issue) provides two signiﬁcant advances. 
First, they have identiﬁed CD24 as an abun-
dant protein present in urinary exosomes 
from humans and mice. CD24 is a small 
glycosyl phosphatidylinositol-anchored 
glycoprotein believed to be involved in 
cell–cell adhesion and signaling. Although 
abundant in urinary exosomes, CD24 was 
not discovered in earlier mass spectrom-
etry–based proﬁling experiments, chieﬂy 
because of its small size and the lack of 
a proﬁle of tryptic peptides of a size that 
would be favorable for identiﬁcation by 
mass spectrometry. Second, Keller and col-
leagues2 have demonstrated that exosomes 
are recoverable from amniotic ﬂuid. It may 
seem self-evident that, if exosomes are 
present in urine, they must be present in 
amniotic ﬂuid as well. However, the ﬁnding 
of exosomes in amniotic ﬂuid provides a 
conceptual spark that may propel investiga-
tors toward studies in which amniotic ﬂuid 
exosomes are used as a means of enrich-
ing markers of disease that can be used for 
prenatal diagnosis.
The process of exosome formation and 
release is illustrated in Figure 1c. Inte-
gral membrane proteins in the plasma 
membrane become mono- (or oligo-) 
ubiquitylated through the action of ubiq-
uitin ligases such as Nedd4-2. The latter 
ubiquitylates the epithelial sodium chan-
nel (ENaC) in connecting tubule and col-
lecting duct cells. The ubiquitylation marks 
the protein for endocytosis by creating a 
site for interaction with ubiquitin-binding 
clathrin adaptor proteins such as proteins 
in the epsin family.8 The cargo in the result-
ing early endosomes is sorted into either 
recycling endosomes or late endosomes/
MVBs. Those destined for the late-endo-
somal pathway bind to the external surfaces 
of MVBs by ubiquitin interaction with 
the ubiquitin receptor proteins HRS and 
Tsg101. The endosome fuses with the outer 
membrane of the MVB and invaginates, 
turning inside out as it becomes an internal 
vesicle of the MVB. The overall process of 
MVB recognition, fusion of the endosome 
with the MVB outer membrane, invagina-
tion, and ﬁssion of the intra-MVB vesicle is 
mediated by a series of protein complexes 
referred to as ‘endosomal sorting complex 
required for transport,’ or ESCRT. Speciﬁ-
cally involved are newly deﬁned ESCRT-0 
(containing HRS), ESCRT-I (containing 
Tsg101), ESCRT-II, and ESCRT-III, as 
well as a protein called ALIX (also known 
as Bro1).9 The intraluminal vesicles of the 
MVBs (‘pro-exosomes’) are then secreted 
from the cell when the outer membrane of 
the MVB fuses with the plasma membrane. 
Of note is the fact that the process of 
invagination from the outer membrane of 
the MVB causes sequestration of cytosolic 
proteins in the pro-exosome lumens. Thus, 
proteomic analysis of urinary exosomes 
Figure 1 | Urinary exosome morphology and biogenesis. (a) Electron micrograph of negatively 
stained urinary exosomes (scale bar, 50 nm). (b) Electron micrograph of a renal inner medullary 
collecting duct cell (scale bar, 100 nm). Uncoated vesicles (asterisks) and coated vesicles (arrow) are 
indicated. MVB, multivesicular body. (c) Schematic of urinary exosome formation and release into 
the urine. E1, ubiquitin-activating enzyme; E2, ubiquitin-conjugating enzyme; E3, ubiquitin-protein 
ligase; AP, adaptor protein; Ub, ubiquitin; CCP, clathrin-coated pit (clathrin molecules are shown in 
green); ESCRT, endosomal sorting complex required for transport; Vps4, vacuolar protein sorting 4; 
ALIX, ALG-2 interacting protein X; ILVs, intraluminal vesicles.
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reveals not only an array of membrane 
proteins from the apical endosomal path-
way of multiple cell types but a variety of 
entrained cytosolic proteins.5 Not sur-
prisingly, urinary exosomes also contain 
ALIX, ubiquitin, and all components of 
the ESCRT-I, ESCRT-II, and ESCRT-III 
complexes (our unpublished data). An 
interesting, important, and unanswered 
question is: What fraction of MVBs that 
form in renal epithelial cells are eliminated 
by this exocytic process versus the classical 
fate of late endosomes, namely, incorpo-
ration into lysosomes for degradation of 
their contents? Another important ques-
tion is: What are the mechanisms by which 
MVBs translocate to the apical region of 
epithelial cells and fuse with the plasma 
membrane? Finally, are there undiscov-
ered or unstudied disorders of exosome 
secretion that may shed light on their 
physiological roles, and are these abnor-
malities related to so-called disorders of 
lysosomal secretion such as Hermansky-
Pudlak syndrome, Griscelli syndrome, 
and Chediak-Higashi syndrome?
Regarding the presence of exosomes in 
urine, it is natural to ask the ‘why’ question: 
Why would evolution select for a process 
that generates and excretes exosomes, as 
opposed to disposing of cellular waste 
materials through degradative processes? 
One answer is the ‘1950s-theory-of-waste-
management’ approach, which consisted 
of getting rid of wastes by dumping them 
into the nearest ﬂowing stream. That is, it 
may be energetically eﬃcient to dispose of 
waste molecules by saving them in MVBs 
and translocating the contents periodi-
cally to the urinary space. Although this 
theory lends itself to graphic metaphors, 
it may not be the right answer. Exosomes 
are very small structures, each with a 
very small radius of curvature (Figure 
1a), which probably requires a signiﬁcant 
amount of energy for formation. There-
fore, it is not self-evident that excretion 
via exosomes is energy eﬃcient. Conse-
quently, it seems useful to look for other 
roles of exosomes beyond that of excretion 
of waste molecules. An intriguing idea was 
recently oﬀered in a paper by Valadi et al.10 
These authors demonstrated that, in addi-
tion to proteins, exosomes isolated from a 
number of cell types contain a variety of 
mRNA and microRNA molecules. It was 
proposed that exosomes provide a means 
by which neighboring cells can inﬂuence 
one another’s functions via transfer of 
these RNAs. This kind of model is of obvi-
ous interest in the area of developmental 
biology, where cell–cell interactions are 
critical for the orchestration of the diﬀer-
entiation of many tissues and cells in the 
appropriate sequence. Beyond this, if we 
assume that urinary exosomes also con-
tain speciﬁc mRNAs and microRNAs, it 
is conceivable that day-to-day regulation 
of nephron function could be mediated in 
part through a regulated process of exo-
some secretion and reuptake downstream 
in other cell types, where their component 
mRNA and microRNA molecules would 
alter the overall structure or function 
of the recipient cells. Such a possibility 
deserves examination.
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Measuring the burden of illness 
for end-stage renal disease: some 
heavy lifting required
G de Lissovoy1,2
Estimates for the burden of illness (BOI) attributable to end-stage renal 
disease (ESRD) in Canada are presented in the article by Zelmer. This 
Commentary describes the methodology of BOI analysis, its role in 
formulating public policy, and the potential application to improving 
care for ESRD.
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People value good health, as does society 
overall. For the individual, illness and 
disability diminish the ability to function 
while increasing dependence on others. 
Pain and distress impede the enjoyment of 
life. For society, impaired population health 
reduces productivity and decreases gross 
domestic product. Treatment of disease 
and its broader impact necessitates diver-
sion of communal resources and increases 
tax burden. Individual suﬀering takes a toll 
on the national psyche.
Burden-of-illness (BOI) analysis involves 
methods for quantifying the societal 
impact of disease, disability, injury, and 
other forms of impaired health. Analysis of 
